Soroka Medical Center, Beer Sheba, Israel.
Ben-Gurion University, Beer Sheba, Israel.
Eur J Haematol. 2018 Oct;101(4):502-507. doi: 10.1111/ejh.13134. Epub 2018 Aug 31.
To ascertain the relevance of bone marrow cellularity (BMC) to the interpretation of blast percentage (blast%) in MDS prognostication.
We compared survival prediction based on blast% adjusted to different levels of cellularity, compared to the survival based on the original IPSS-R blast% grouping.
We analyzed 355 consecutive MDS patients. Cellularity, in and of itself or its interaction with blast%, was not associated with overall survival (OS). In a small subset of patients with a hypercellular marrow (15%; n = 26), dismal prognosis was observed at lower levels of blast%. For these cases OS was similar to higher IPSS-R blast groups. For example, within the Intermediate group (blast% 5%-10%), those with a hypercellular marrow and >6% blasts had an OS of 10 m similar to 16 m in the High (blast% 10%-19%) blast group. These changes did not translate into a significant improvement in overall prognostic power of a cellularity-adjusted IPSS-R (C index 0.71 vs. 0.70).
Adjusting blast% to cellularity did not improve prognostication. However, within IPSS-R-defined blast groups, a small subset of patients with relatively higher blast% and hypercellularity may have a worse prognosis than expected.
确定骨髓细胞(BMC)与 MDS 预后中原始核细胞百分比(blast%)解释的相关性。
我们比较了基于不同细胞程度调整后的 blast%的生存预测,以及基于原始 IPSS-R blast%分组的生存预测。
我们分析了 355 例连续 MDS 患者。细胞程度本身或其与 blast%的相互作用与总生存率(OS)无关。在骨髓细胞增生程度较高的一小部分患者(15%;n=26)中,较低的 blast%水平预示着预后不良。对于这些病例,OS 与更高的 IPSS-R blast 组相似。例如,在中间组(blast% 5%-10%)中,骨髓细胞增生程度较高且有>6%的原始核细胞的患者的 OS 为 10m,与高(blast% 10%-19%)blast 组的 16m 相似。这些变化并没有显著提高细胞程度调整后的 IPSS-R 的整体预后能力(C 指数 0.71 与 0.70)。
调整 blast%至细胞程度并不能改善预后。然而,在 IPSS-R 定义的 blast 组内,一小部分相对较高的 blast%和骨髓细胞增生程度较高的患者可能比预期的预后更差。